rodatristat ethyl
Phase 2- Indications
- Pulmonary arterial hypertension
Company intelligence / Profile preview
Altavant Sciences
Cary, North Carolina, United Statesorpha.net ↗
- Ownership
- Private
- Employees
- ~3
- Development stage
- Phase 2
01
Overview
Altavant Sciences has advanced its lead candidate rodatristat ethyl to Phase 2 clinical trials for pulmonary arterial hypertension. Its second program, ALTA‑2530, an inhaled IL‑1 receptor antagonist for bronchiolitis obliterans syndrome post-lung transplant, remains in preclinical development with promising nonclinical data on lung exposure and delivery via nebulizer. The company emphasizes patient-centric drug development and has engaged patients directly to inform its BOS/CLAD research
- Therapeutic areas
- PulmonologyCardiovascular
- Modalities
- Small molecule drugsProtein drugs (including large molecules such as IL1R1 antagonists)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
No major external partnerships disclosed beyond parent company relationships.
Beyond the preview
Go deeper on Altavant Sciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Altavant Sciences.